← Browse by Condition
Medical Condition
chronic lymphocytic leukemia
Total Trials
14
Recruiting Now
14
Trial Phases
Phase 2, Phase 1, Phase 3
Leukemia clinical trials cover acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), and chronic lymphocytic leukemia (CLL) — distinct diseases with profoundly different biology and treatment approaches. AML research focuses on targeted agents for FLT3, IDH1/2, and TP53-mutated disease, while CLL trials explore fixed-duration venetoclax combinations that achieve treatment-free remissions.
Active trials investigate menin inhibitors for NPM1/KMT2A AML, magrolimab (anti-CD47) combinations, bispecific antibodies in relapsed ALL, and next-generation BTK inhibitors (pirtobrutinib) for ibrutinib-resistant CLL. MRD (minimal residual disease) negativity is emerging as a regulatory endpoint to accelerate approvals.
Frequently Asked Questions — chronic lymphocytic leukemia Clinical Trials
How many clinical trials are currently recruiting for chronic lymphocytic leukemia?
ClinicalMetric currently tracks 14 actively recruiting clinical trials for chronic lymphocytic leukemia, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 14. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for chronic lymphocytic leukemia?
chronic lymphocytic leukemia research spans Phase 1 (2 trials), Phase 2 (2 trials), Phase 3 (3 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a chronic lymphocytic leukemia clinical trial?
Eligibility criteria for chronic lymphocytic leukemia trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1 2
Phase 2 2
Phase 3 3
Top Sponsors
2 trials
1 trial
1 trial
1 trial
1 trial
Recruiting Clinical Trials
NCT06792994
Recruiting
A Prospective Observational Trial to Assess Treatment Sequences and Factors That Impact Overall Sur-vival in Patients With Chronic Lymphocytic Leukaemia (CLL) Treated Within First-line Studies of the GCLLSG
Enrollment
2,000 pts
Location
Germany
Sponsor
German CLL Study Group
NCT06333262 Phase 2
Recruiting
Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia
Enrollment
60 pts
Location
United States
Sponsor
Inhye Ahn
NCT01853631 Phase 1
Recruiting
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
Enrollment
64 pts
Location
United States
Sponsor
Baylor College of Medicine
NCT04269902 Phase 3
Recruiting
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Enrollment
247 pts
Location
United States, Canad...
Sponsor
National Cancer Institute (NCI...
NCT04282811
Recruiting
Observational Study Relapsed or Refractory Chronic Lymphocytic Leukemia Venetoclax-based Regimens Outside Clinical Trials in Italy
Enrollment
321 pts
Location
Italy
Sponsor
Gruppo Italiano Malattie EMato...
NCT06588478 Phase 2
Recruiting
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Enrollment
249 pts
Location
United States, Austr...
Sponsor
Loxo Oncology, Inc.
NCT06136559 Phase 3
Recruiting
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Enrollment
1,200 pts
Location
United States, Austr...
Sponsor
Merck Sharp & Dohme LLC
NCT05334069
Recruiting
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Enrollment
2,000 pts
Location
United States
Sponsor
Alliance for Clinical Trials i...
NCT05371808
Recruiting
Economic Analysis of Early vs Delayed Therapy in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma:
Enrollment
247 pts
Location
Canada
Sponsor
Canadian Cancer Trials Group
NCT07099443
Recruiting
Determinants of the Response to BTK Degraders (BTKd) in Chronic Lymphocytic Leukemia
Enrollment
60 pts
Location
France
Sponsor
Nantes University Hospital
NCT06536452
Recruiting
Hematopoiesis in MBL and CLL Versus Healthy Age-Matched Control Subjects
Enrollment
50 pts
Location
United States
Sponsor
Mayo Clinic
NCT06943872 Phase 3
Recruiting
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Enrollment
630 pts
Location
United States, Argen...
Sponsor
BeOne Medicines
NCT06151730
Recruiting
Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study
Enrollment
100 pts
Location
United States
Sponsor
Mayo Clinic
NCT05602363 Phase 1
Recruiting
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Enrollment
120 pts
Location
United States
Sponsor
Carna Biosciences, Inc.
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology